PhenomeX (CELL) Action Cours

L’action PhenomeX (CELL) est cotée sur 4 places boursières, notamment : NASDAQ (BLI), Frankfurt (64B.F), München (64B.MU), Düsseldorf (64B.DU).

Berkeley Lights Inc (BLI) is a company specializing in the development of cell-based solutions for the biotech and pharma sector. The company offers a unique platform technology called Beacon, which allows for the identification, selection, and isolation of individual cells. BLI's business model is based on three pillars: the Beacon platform, its associated services, and consumer goods. The Beacon platform is the core of the business model. It consists of an automated unit that allows for the manipulation of cells at a rate of up to 10,000 per second. The platform is based on a combination of microfluidics, electronics, and optical technology. The associated services refer to the application of the Beacon platform in various areas. The company offers its customers the opportunity to analyze their own cells on the platform, with the goal of providing them with a better understanding of their cell functions. The procedure is used to identify, characterize, and isolate active substances. In addition, the company offers services for the development of biological therapeutics and vaccines. As the third pillar of the business model, the company offers consumer goods. Over time, BLI has developed a variety of consumables that are required for use on the Beacon platform. These include microchips, reagents, and media. The consumer goods are an important source of revenue for the company and constitute a significant portion of its overall income. Berkeley Lights Inc serves a variety of industries, including biotech and pharmaceutical companies, academic institutions, and government agencies. BLI's platform technology is utilized in many areas, including cell expression, gene editing, cell line development, immunotherapy, and antibody research. The Beacon technology offers a wide range of applications and is an important platform for biotech and pharma research. Although Berkeley Lights Inc is a relatively young company, it has quickly become a key partner for innovative medical research. The company has proven its ability to bring groundbreaking technology to market, which can support biotech and pharma research in many ways. The Beacon platform provides engineers, researchers, and scientists with a fast and effective method for the characterization and isolation of cells, enabling them to develop better therapies and vaccines. In this context, it should be mentioned that Berkeley Lights Inc is listed on the Nasdaq stock exchange and has experienced strong growth. The company has impressed investors with its innovative technology and forward-looking business model. With the Beacon technology, the company makes an important contribution to biotech and pharma research and helps to develop new drugs and therapies that can cure a wide range of diseases. In summary, the Beacon platform is a unique and versatile tool for optimizing cell analysis and the development of therapeutics. With a well-balanced strategy of platform development, services, and consumer goods, the company offers a wide range of solutions for various industries. Furthermore, Berkeley Lights Inc actively contributes to the exploration of therapeutics that can help many patients with different diseases.

Le chiffre d'affaires ne peut pas être calculé pour PhenomeX pour le moment.

Le bénéfice ne peut pas être calculé pour PhenomeX pour le moment.

Le ratio P/E ne peut pas être calculé pour PhenomeX pour le moment.

Le ratio P/S ne peut pas être calculé pour PhenomeX pour le moment.

Le score de qualité Eulerpool pour PhenomeX est de 3/10.

L'ISIN de PhenomeX est US0843101017. L'ISIN (International Securities Identification Number) est un identifiant global unique pour les titres.

Le WKN de PhenomeX est A2P9RR. Le WKN (Wertpapierkennnummer) est un numéro allemand d'identification des titres à six chiffres.

Le symbole boursier de PhenomeX est CELL. Ce code boursier est utilisé pour négocier les actions PhenomeX à la bourse.